Evaluate Pharma offers clients forecasts of the pharma industry in its annual World Preview.
The top 10 R&D spenders for 2024:
1. Johnson & Johnon ($9.9 billion)
2. Roche ($9.9 billion)
3. Merck ($9.2 billion)
4. Novartis ($9.2 billion)
5. Pfizer ($8.9 billion)
6. GlaxoSmithKline ($6.8 billion)
7. Bristol-Myers Squibb ($6.7 billion)
8. Sanofi ($6.7 billion)
9. Eli Lilly ($6.1 billion)
10. AstraZeneca ($5.9 billion)
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
